Anna Rowe

Medicine & Life Sciences

1. timolumab 100%
2. namilumab 63%
3. Sclerosing Cholangitis 56%
4. Coronavirus 33%
5. Infliximab 31%
6. Patient Reported Outcome Measures 29%
7. SARS Virus 26%
8. Standard of Care 25%
9. C-Reactive Protein 24%
10. Blood Vessels 20%
11. Clinical Trial Protocols 20%
12. Phase II Clinical Trials 18%
13. Research Ethics Committees 16%
14. Alkaline Phosphatase 15%
15. Safety 15%
16. Feasibility Studies 13%
17. Monoclonal Antibodies 13%
18. Therapeutics 12%
19. Proteins 12%
20. Pneumonia 12%
21. Arm 11%
22. Ethics 11%
23. X Ray Computed Tomography 10%
24. Health Care Outcome Assessment 10%
25. Liver Diseases 10%
26. Immunomodulation 10%
27. Clinical Trials 9%
28. Publications 9%
29. Liver Cirrhosis 9%
30. Biomarkers 8%
31. Serum 7%
32. Reverse Transcription 7%
33. Patient Care 7%
34. Health Status 7%
35. Inflammation 7%
36. Monocytes 7%
37. Congresses 7%
38. Interviews 7%
39. Fibrosis 6%
40. Public Health 6%
41. National Institutes of Health (U.S.) 6%
42. Macrophages 6%
43. Thorax 6%
44. Liver 5%
45. Peer Review 5%
46. Wounds and Injuries 5%
47. Polymerase Chain Reaction 5%
48. Patient Participation 5%
49. Infections 5%